The shares of a company engaged in nutraceuticals, personalized healthcare, preventive wellness, and digital health solutions hit a 2% upper circuit after its Board approved the launch of Brain Fuel Capsules.
With a market capitalization of Rs 1,156 crore, the share price of Aayush Wellness Ltd hit upper circuit of 2% to Rs 242.30 per share from its previous closing price of Rs 237.55 per share. The stock is currently classified under GSM (Graded Surveillance Measure): Stage 0 and ESM (Enhanced Surveillance Measure): Stage 2.
What’s the News
Aayush Wellness Ltd has announced the launch of Brain Fuel Capsules, approved by its Board on July 11, 2025. This new product follows the successful launch of Sleep Gummies and Beauty Gummies, and aligns with the company’s strategy to tap into India’s $18 billion nutraceutical industry, growing at a CAGR of over 15%. The brain health segment, projected to grow at 14.78% CAGR, is a key focus area, driven by rising mental health concerns and lifestyle-related cognitive issues.
Management Commentary
“We believe that true wellness starts from within, and brain health is central to overall well-being,” said Naveena Kumar, Managing Director of Aayush Wellness Limited.
“With the launch of Brain Fuel Capsules, we are offering a time-tested solution to one of the most pressing challenges of our generation — cognitive fatigue driven by modern lifestyles. This herbal formulation supports long-term mental clarity without the side effects of synthetic alternatives.”
About the Company
Aayush Wellness Limited, established in 1989, is an integrated healthcare company focused on nutraceuticals, personalized healthcare, preventive wellness, and digital health solutions. The company is dedicated to promoting healthier lifestyles through innovative and high-quality wellness products.
Its product range includes Dreamy Sleep Gummies for better sleep, Beauty Vitamin Gummies for skin, hair, and nail health, and Herbal Pan Masala as a refreshing mouth freshener. Aayush Wellness continues to expand its offerings to meet the rising demand for natural and preventive health solutions in India.
The company reported a revenue of Rs 73.35 crore in FY25, up by 12,125% from its FY24 revenue of Rs 0.60 crore. Coming to its profitability, the company reported a net profit rise of 491% to Rs 3.37 crore in FY25 from Rs 0.57 crore in FY24.
It maintains a healthy financial profile with a ROCE of 52.5% and ROE of 51.1%, reflecting efficient capital and equity utilization. The stock has delivered around 13,900% return in the last two years.
Written By Rohan Pandey
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
